The introduction of beta-blockers into heart failure therapy is one of the most instructive paradigm shifts in clinical pharmacology. For decades, beta-blockers were considered absolutely contraindicated in heart failure: the logic being that a failing heart needed every molecule of sympathetic drive it could recruit to maintain output.1 The recognition that this sympathetic activation was itself the poison, not the antidote, transformed not only HF therapy but the broader understanding of neurohormonal disease progression. Three beta-blockers, carvedilol, metoprolol succinate, and bisoprolol, have been rigorously proven to reduce all-cause mortality in HFrEF in large randomized controlled trials. No other beta-blocker has this evidence and none should be substituted.2 This module covers the pharmacological rationale, the landmark trial evidence, practical initiation and titration, management of common complications, and the nuances of beta-blocker use in challenging clinical scenarios.
In heart failure with reduced ejection fraction, the sympathetic nervous system is chronically activated in proportion to the severity of ventricular dysfunction. Plasma norepinephrine levels, a surrogate for sympathetic nervous system (SNS) activation, correlate directly with NYHA functional class and are one of the strongest independent predictors of mortality in HF, as established by Cohn et al. in 1984.3 Acutely, this sympathetic activation serves an adaptive purpose: beta-1 adrenergic receptor stimulation increases heart rate and contractility (positive chronotropy and inotropy), and alpha-1 stimulation increases systemic vascular resistance to maintain blood pressure. These responses sustain perfusion in the short term. Chronically, however, sustained catecholamine excess becomes directly cardiotoxic through multiple mechanisms: calcium overload via L-type channel overstimulation leading to cardiomyocyte apoptosis and necrosis; mitochondrial dysfunction from sustained beta-1 activation and oxidative stress; progressive downregulation and uncoupling of beta-1 adrenergic receptors (reducing intrinsic inotropic reserve); proarrhythmic electrophysiological remodeling through increased automaticity and triggered afterdepolarizations; and further amplification of renin-angiotensin-aldosterone system (RAAS) activation through beta-1-mediated renin release from the juxtaglomerular apparatus.1 The cumulative effect is a self-perpetuating cycle: low cardiac output → SNS activation → myocardial toxicity → further reduction in cardiac output.
Beta-blockade interrupts this cycle not through hemodynamic improvement (beta-blockers are negative inotropes and acutely worsen cardiac output) but through neurohormonal modification. By blocking the beta-1 receptor, these drugs: (1) attenuate catecholamine-mediated cardiomyocyte injury; (2) allow beta-1 receptor re-expression and upregulation over weeks to months, restoring intrinsic adrenergic reserve; (3) reduce heart rate, prolonging diastolic filling time and reducing myocardial oxygen consumption; (4) reduce RAAS activation by blocking juxtaglomerular renin release; and (5) have antiarrhythmic effects through slowing of the sinoatrial node and reduced ventricular ectopy.1 The clinical consequence is that left ventricular ejection fraction (LVEF), which may transiently worsen with beta-blocker initiation, typically improves significantly over 3–6 months of sustained therapy, with the greatest LVEF gains seen in patients with the lowest baseline LVEF. This phenomenon of beta-blocker-mediated reverse remodeling is among the most compelling demonstrations of the neurohormonal hypothesis of HF.
Only three beta-blockers have demonstrated all-cause mortality reduction in HFrEF in Class I-level randomized controlled trials and are guideline-approved for this indication: carvedilol, metoprolol succinate (extended-release), and bisoprolol.2 These three must never be considered interchangeable with other beta-blockers (e.g., atenolol, metoprolol tartrate, propranolol) for the HF indication. The evidence is agent-specific, not class-specific.
Pharmacology: Carvedilol is a non-selective beta-blocker (beta-1 and beta-2 blockade) with additional alpha-1 adrenergic receptor blocking activity, providing vasodilation that partially offsets the negative hemodynamic effects of beta-blockade. It is also a potent antioxidant.2 Carvedilol is lipophilic, undergoes extensive first-pass hepatic metabolism, and is administered twice daily. It does not have intrinsic sympathomimetic activity (ISA). The alpha-1 blockade distinguishes carvedilol from bisoprolol and metoprolol succinate and accounts for its vasodilatory properties and its relatively greater tendency to cause hypotension during titration. Dosing: Starting dose 3.125 mg twice daily (regardless of weight for most adults); target dose 25 mg twice daily (patients ≤85 kg) or 50 mg twice daily (patients >85 kg). Double the dose every 2 weeks as tolerated.2 Evidence: The COPERNICUS trial (2001) enrolled 2,289 patients with severe HFrEF (LVEF <25%, NYHA class III–IV, euvolemic at enrollment) and demonstrated that carvedilol reduced all-cause mortality by 35% (HR 0.65; 95% CI 0.52–0.81; p<0.001).4 This population had previously been considered too ill for beta-blockade: COPERNICUS refuted the idea that very low LVEF or advanced symptoms precluded beta-blocker therapy. The US Carvedilol Heart Failure Trials program (1996) also demonstrated mortality benefit and formed the basis for FDA approval.
Pharmacology: Metoprolol succinate is a highly selective beta-1 adrenergic receptor blocker with no alpha-1 blocking activity and no ISA. Its extended-release formulation provides sustained, once-daily beta-1 blockade with less peak-to-trough variation than the immediate-release tartrate salt.2 Metoprolol tartrate (immediate-release) is NOT an approved substitute for metoprolol succinate in HF: the two formulations have distinct pharmacokinetic profiles and the tartrate form was not used in the MERIT-HF trial. This distinction is clinically critical and frequently confused in practice. Dosing: Starting dose 12.5–25 mg once daily (12.5 mg for NYHA class III–IV); target dose 200 mg once daily. Double the dose every 2 weeks as tolerated.2 Evidence: The MERIT-HF trial (1999) enrolled 3,991 patients with symptomatic HFrEF (LVEF ≤40%, NYHA class II–IV) on background ACEi and diuretics.5 Metoprolol succinate reduced all-cause mortality by 34% (relative risk 0.66; 95% CI 0.53–0.81; p<0.001). The trial was stopped early due to the magnitude of benefit. Sudden death was reduced by 41%, and death from progressive HF was reduced by 49%.5
Pharmacology: Bisoprolol is a highly selective beta-1 adrenergic receptor blocker, arguably the most beta-1 selective of the three approved agents, with no alpha-1 blocking activity and no ISA. Its high beta-1 selectivity makes it the preferred choice in patients with significant reactive airway disease where any residual beta-2 blockade is particularly undesirable.2 Bisoprolol is predominantly renally excreted; dose adjustment may be needed in severe renal impairment. Once-daily dosing. Dosing: Starting dose 1.25 mg once daily; target dose 10 mg once daily. Titrate every 2 weeks as tolerated.2 Evidence: The CIBIS-II trial (1999) enrolled 2,647 patients with symptomatic HFrEF (LVEF ≤35%, NYHA class III–IV) on background ACEi and diuretics.6 Bisoprolol reduced all-cause mortality by 34% (HR 0.66; 95% CI 0.54–0.81; p<0.0001). The trial was stopped early due to benefit. Sudden cardiac death was reduced by 44%.6
The three approved agents are not identical in their pharmacology, and their distinctions have practical implications: Receptor selectivity: Carvedilol is non-selective (beta-1, beta-2, alpha-1). Metoprolol succinate and bisoprolol are beta-1 selective. In patients with asthma or severe COPD, carvedilol's beta-2 blockade carries the highest risk of bronchospasm; bisoprolol's superior beta-1 selectivity makes it the safest choice, though all three must be used with caution in active bronchospasm. In patients with peripheral artery disease, non-selective blockade with carvedilol theoretically worsens peripheral vasoconstriction, though clinical significance is debated; bisoprolol or metoprolol succinate are preferred. Vasodilation: Carvedilol's alpha-1 blocking activity provides vasodilation, making it particularly useful in patients with hypertension concurrent with HF. However, it also causes more hypotension during titration, particularly in the setting of volume depletion. Lipid effects: Carvedilol is favorable on lipid profiles (alpha-1 blockade improves insulin sensitivity and reduces LDL oxidation). Metoprolol succinate and bisoprolol are relatively neutral. This distinction has modest clinical relevance given the broad use of statins in HF populations.
3,991 patients with HFrEF (LVEF ≤40%, NYHA class II–IV) on optimized background therapy (ACEi in ~90%, diuretics in ~90%).5 Randomized to metoprolol succinate CR/XL vs. placebo. Primary endpoint (all-cause mortality): RR 0.66 (95% CI 0.53–0.81; p<0.001). Number needed to treat (NNT) to prevent one death: approximately 26 patients over 1 year. Secondary endpoints: sudden death reduced 41%; death from worsening HF reduced 49%; HF hospitalizations reduced 35%.5 The LVEF improved significantly in the metoprolol group over the 12-month follow-up period. The trial was stopped early after a median follow-up of 1 year due to the pre-specified stopping criterion being met.
2,289 patients with severe HFrEF (LVEF <25%, NYHA class III–IV, no fluid overload or IV therapy within 4 days of enrollment).4 Randomized to carvedilol vs. placebo on background ACEi and diuretics. All-cause mortality: HR 0.65 (95% CI 0.52–0.81; p<0.001), corresponding to a 35% relative risk reduction. Composite of death or all-cause hospitalization: reduced 24%. Despite a mean LVEF of only 20%, carvedilol was well tolerated and actually improved LVEF significantly. COPERNICUS definitively established that severe systolic dysfunction is not a contraindication to beta-blocker therapy.4
2,647 patients with HFrEF (LVEF ≤35%, NYHA class III–IV).6 Randomized to bisoprolol vs. placebo on background ACEi and diuretics. All-cause mortality: HR 0.66 (95% CI 0.54–0.81; p<0.0001), a 34% relative risk reduction. Sudden cardiac death: reduced 44%. HF hospitalizations: reduced 20%. CIBIS-II was also stopped early due to benefit. Of note, approximately 20% of enrolled patients had COPD: bisoprolol's high beta-1 selectivity was associated with no excess of respiratory adverse events compared to placebo in this subgroup.6
3,029 patients with HFrEF randomized to carvedilol vs. metoprolol tartrate (immediate-release, NOT succinate).7 Carvedilol reduced all-cause mortality by 17% relative to metoprolol tartrate (HR 0.83; 95% CI 0.74–0.93; p=0.0017). This trial is frequently cited as evidence of carvedilol superiority but is methodologically limited: the comparator was metoprolol tartrate at submaximal doses, not metoprolol succinate at the target doses used in MERIT-HF. The results cannot establish superiority of carvedilol over metoprolol succinate at guideline-recommended doses, and the three agents remain considered equivalent by current guidelines.2
Beta-blockers must only be initiated in patients who are: (1) clinically euvolemic: no evidence of active fluid overload (resting tachycardia from congestion, elevated jugular venous pressure (JVP), significant peripheral edema); (2) hemodynamically stable: no IV inotrope dependence, systolic blood pressure (SBP) ≥85–90 mmHg; (3) not hospitalized for acute decompensated HF: beta-blockers should not be started during decompensation, though they may be continued (at reduced dose if necessary) in patients already taking them who are admitted with mild-to-moderate decompensation.2 Initiating a beta-blocker in an actively decompensated patient risks acute hemodynamic deterioration.
Begin at the lowest available dose. Double the dose every 2 weeks, provided the patient remains euvolemic, hemodynamically stable (SBP ≥90 mmHg without symptoms of hypoperfusion), and without worsening symptoms of HF. There is no urgency to reach the target dose rapidly; the priority is tolerability. Clinical monitoring at each titration visit: resting heart rate (target resting HR 55–65 bpm in stable patients), blood pressure, volume status (weight, JVP, peripheral edema), and symptoms. Beta-blockers should be up-titrated toward but not necessarily to the maximum dose if tolerability limits progression: even submaximal doses provide survival benefit.2 The MERIT-HF trial demonstrated significant mortality reduction at an average dose of 159 mg/day (below the 200 mg target in some patients).
Worsening fluid retention: The most common early problem. If the patient develops weight gain or increasing edema after a dose increase, increase the loop diuretic dose transiently; do not automatically reduce the beta-blocker dose. If fluid retention persists despite diuretic adjustment, reduce the beta-blocker to the previous tolerated dose and attempt re-titration after 4 weeks.2 Hypotension: Beta-blocker initiation lowers blood pressure through multiple mechanisms (reduced heart rate, reduced cardiac output, reduced peripheral resistance with carvedilol). If asymptomatic hypotension develops (SBP 85–95 mmHg without dizziness or presyncope), it can be managed by reviewing other antihypertensive medications, reducing the diuretic dose to increase preload, separating the beta-blocker and ARNI/ACEi dosing by several hours, and accepting a lower titration endpoint. Symptomatic hypotension requires dose reduction. Bradycardia: A resting HR <55 bpm that is asymptomatic rarely requires intervention. If bradycardia is symptomatic (fatigue, dizziness, presyncope), reduce the dose. Always check for concurrent rate-slowing medications (digoxin, amiodarone, ivabradine, non-dihydropyridine CCBs) that may compound the effect. Fatigue: A common early complaint in the first 4–6 weeks, often representing beta-2 blockade effects (reduced skeletal muscle perfusion, blunted sympathetic exercise augmentation). Fatigue typically resolves as the cardiovascular state stabilizes. Counsel patients proactively and avoid dose reduction for fatigue alone unless it is severely limiting.2
This is one of the most clinically important scenarios. In a patient admitted with decompensated HF who is already taking a beta-blocker, the default decision should be to continue the beta-blocker at the current dose (or reduce; not stop) unless the patient is in cardiogenic shock or requires IV inotropes.2 Abrupt discontinuation of a beta-blocker in a patient with established HFrEF is associated with rebound SNS activation, arrhythmia, and increased short-term mortality. If IV inotropes are required (dobutamine, milrinone), temporarily reducing or suspending the beta-blocker is appropriate. Once the patient is euvolemic and inotropes are weaned, the beta-blocker should be reinitiated at a low dose before discharge.
Beta-blockers provide ventricular rate control in HF patients with AF and reduce the risk of rapid ventricular response during exercise or sympathetic activation. All three approved HF beta-blockers provide adequate rate control in AF. The target resting ventricular rate in HF with AF is generally ≤80 bpm at rest and ≤110 bpm with moderate exertion, though individualized targets are appropriate based on symptoms and hemodynamics. An important nuance: in patients with HF and AF, several rhythm-control trials (including AFFIRM and AF-CHF) showed no mortality advantage of rhythm control over rate control, though more recent data from CASTLE-AF and EAST-AFNET 4 have renewed interest in rhythm control, particularly catheter ablation, in selected HF patients.2 Non-dihydropyridine calcium channel blockers (diltiazem, verapamil) must not be used for rate control in HFrEF due to their negative inotropic effects; beta-blockers are the preferred rate-controlling agents in this setting.
COPD is present in approximately 20–30% of HF patients and historically deterred clinicians from prescribing beta-blockers.6 However, the net benefit of beta-blockade in HFrEF almost certainly outweighs the risk of modest bronchospasm in most patients with mild-to-moderate COPD. Current guidelines recommend using a highly beta-1 selective agent (bisoprolol preferred) at the lowest effective dose, with careful monitoring for respiratory symptoms.2 Beta-blockers are contraindicated in active bronchospasm but are not contraindicated in stable COPD. Patients with severe asthma or reactive airway disease with a strong bronchospasm component represent a more challenging group; the decision must be individualized.
Beta-blockers should not be initiated in patients with hemodynamically significant low cardiac output (cardiogenic shock, very low BP, evidence of end-organ hypoperfusion). In patients with chronic low-output states who are already established on beta-blockers, dose reduction (not discontinuation) is the preferred strategy during mild decompensation.2 The theoretical concern that withdrawing negative inotropic drugs will improve cardiac output in acute low-output states must be balanced against the well-established risks of beta-blocker withdrawal.
Beta-blockers blunt the adrenergic symptoms of hypoglycemia (tachycardia, tremor) and may delay recovery from hypoglycemia in insulin-dependent diabetic patients. Selective beta-1 agents (bisoprolol, metoprolol succinate) carry less risk of masking hypoglycemia symptoms than non-selective carvedilol (which also blocks beta-2). Carvedilol has the additional advantage of improved insulin sensitivity through its alpha-1 blocking effects. In clinical practice, all three approved agents are used in diabetic HF patients with appropriate education about hypoglycemia monitoring.2
COPERNICUS established that carvedilol is safe and effective in patients with LVEF as low as 10–15% when patients are euvolemic.4 The key requirement is euvolemia and hemodynamic stability at initiation, not the absolute LVEF value. Clinicians should not deny beta-blocker therapy to patients with severely reduced LVEF provided the prerequisites for initiation are met.
Bristow MR. Treatment of chronic heart failure with β-adrenergic receptor antagonists: a convergence of receptor pharmacology and clinical cardiology. Circ Res. 2011;109(10):1176–1194
doi:10.1161/CIRCRESAHA.111.245092Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure. J Am Coll Cardiol. 2022;79(17):e263–e421
doi:10.1016/j.jacc.2021.12.012Cohn JN, Levine TB, Olivari MT, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med. 1984;311(13):819–823
doi:10.1056/NEJM198409273111303Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure (COPERNICUS). N Engl J Med. 2001;344(22):1651–1658
doi:10.1056/NEJM200105313442201MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353(9169):2001–2007
doi:10.1016/S0140-6736(99)04440-2CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999;353(9146):9–13
doi:10.1016/S0140-6736(98)11181-9Poole-Wilson PA, Swedberg K, Cleland JG, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET). Lancet. 2003;362(9377):7–13
doi:10.1016/S0140-6736(03)13800-7McDonagh TA, Metra M, Adamo M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599–3726
doi:10.1093/eurheartj/ehab368